Crystalline LFA-1 Inhibitor Forms for Rapid Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for disorders mediated by LFA-1 and ICAM interactions lack effective inhibitors with rapid systemic clearance, leading to unwanted systemic effects and limited localized treatment options.
Innovation Solution
Development of a compound with crystalline forms (Forms A, B, C, D, E) and amorphous form of Formula I, offering high purity and rapid systemic clearance, which can be formulated into pharmaceutical compositions for localized treatment of inflammatory and immune-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If existing LFA-1 and ICAM interaction inhibitors are used, then therapeutic effect is achieved, but systemic clearance is slow leading to unwanted systemic effects
Solution Approach 1:
The patent modifies the chemical structure of LFA-1 inhibitors by introducing specific crystalline forms (Forms A, B, C, D, E) with distinct physical properties. These crystalline forms exhibit enhanced solubility and rapid systemic clearance compared to amorphous forms, thereby reducing systemic side effects while maintaining therapeutic efficacy at the localized site of action.
Solution Approach 2:
The invention utilizes phase transition from amorphous to crystalline form to alter the pharmacokinetic properties of the inhibitor. The crystalline forms undergo rapid dissolution and clearance from the system, preventing prolonged systemic exposure and associated harmful effects, while still providing sustained local therapeutic benefit.
2Manufacturing precision
If crystalline forms are developed to improve purity and stability, then manufacturing precision is improved, but formulation complexity increases
Solution Approach 1:
The patent segments the crystalline forms into distinct types (Forms A, B, C, D, E), each with specific X-ray diffraction patterns and physical properties. This segmentation allows selective use of appropriate forms for different therapeutic indications, simplifying formulation development by matching specific form characteristics to specific therapeutic needs rather than requiring all possible forms.
Solution Approach 2:
The invention changes the physical state parameter from amorphous to crystalline, which simultaneously improves purity and stability. The crystalline forms are obtained through controlled crystallization processes that yield high-purity compounds with defined melting points and X-ray patterns, facilitating standardized manufacturing while maintaining formulation simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits LFA-1 interactions with ICAM, providing localized therapeutic benefits with minimal systemic activity, thus addressing the limitations of existing treatments by ensuring targeted delivery and reduced systemic side effects.
Implementation Method 1
crystalline form (Form A) comprising an X-ray powder diffraction pattern having characteristic peaks at a reflection angle 2θ of about 18.2, 21.4, and 22.7 degrees
Implementation Method 2
the crystalline form (Form A) undergoes a predominant endotherm at about 145° C.
Data Source
AI summary
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.